US20040087657A1 - Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors - Google Patents

Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors Download PDF

Info

Publication number
US20040087657A1
US20040087657A1 US10/273,401 US27340102A US2004087657A1 US 20040087657 A1 US20040087657 A1 US 20040087657A1 US 27340102 A US27340102 A US 27340102A US 2004087657 A1 US2004087657 A1 US 2004087657A1
Authority
US
United States
Prior art keywords
disease
histone deacetylase
diseases
brain
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/273,401
Other languages
English (en)
Inventor
Victoria Richon
Paul Marks
Richard Rifkind
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/273,401 priority Critical patent/US20040087657A1/en
Assigned to SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH reassignment SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MARKS, PAUL A., RIFKIND, RICHARD A., RICHON, VICTORIA M.
Assigned to SLOAN-KETTING INSTITUTE FOR CANCER RESEARCH reassignment SLOAN-KETTING INSTITUTE FOR CANCER RESEARCH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MARKS, PAUL A., RIFKIND, RICHARD A, RICHON, VICTORIA A.
Publication of US20040087657A1 publication Critical patent/US20040087657A1/en
Priority to US11/282,420 priority patent/US7879865B2/en
Priority to US13/017,447 priority patent/US20110124731A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • HDACs histone deacetylase
  • HDAC inhibitors fall into four general classes: 1) short-chain fatty acids (e.g., 4-phenylbutyrate and valproic acid); hydroxamic acids (e.g., SAHA, Pyroxamide, trichostatin A (TSA), oxamflatin and CHAPs, such as, CHAP1 and CHAP 31); 3) cyclic tetrapeptides (Trapoxin A and Apicidin); 4) benzamides (e.g., MS-275); and other compounds such as Scriptaid. Examples of such compounds can be found in U.S. Pat. No. 5,369,108, issued on Nov. 29, 1994, U.S. Pat. No. 5,700,811, issued on Dec. 23, 1997, and U.S. Pat.
  • Preferred hydroxamic acid based HDAC inhibitors are suberoylanilide hydroxamic acid (SAHA) and pyroxamide.
  • SAHA has been shown to bind directly in the catalytic pocket of the histone deacetylase enzyme.
  • SAHA induces cell cycle arrest, differentiation and/or apoptosis of transformed cells in culture and inhibits tumor growth in rodents.
  • SAHA is effective at inducing these effects in both solid tumors and hematological cancers. It has been shown that SAHA is effective at inhibiting tumor growth in animals with no toxicity to the animal.
  • the SAHA-induced inhibition of tumor growth is associated with an accumulation of acetylated histones in the tumor.
  • SAHA is effective at inhibiting the development and continued growth of carcinogen-induced (N-methylnitrosourea) mammary tumors in rats.
  • SAHA was administered to the rats in their diet over the 130 days of the study.
  • SAHA is a nontoxic, orally active antitumor agent whose mechanism of action involves the inhibition of histone deacetylase activity.
  • HDAC inhibitors for example, SAHA and pyroxamide can cross the blood brain barrier at sufficient amounts to significantly inhibit HDAC activity causing the accumulation of acetylated histones in the brain. This discovery therefore provides for the use of HDAC inhibitors in the treatment of disorders of the central nervous system including cancer of the brain and neurodegenerative diseases.
  • the present application is directed to a method of treating diseases of the central nervous system (CNS) comprising administering to a individual in need of treatment a therapeutically effective amount of an inhibitor of histone deacetylase.
  • the CNS disease is a neurodegenerative disease.
  • the neurogenerative disease is an inherited neurodegenerative disease, such as those inherited neurodegenerative diseases which are polyglutamine expansion diseases.
  • the individual can be a mammal such as a primate or human.
  • FIG. 1 is a scan of a Western blot and Coomassie stained gel indicating levels of acetylated histone ( ⁇ AcH3) at the indicated timepoints following treatment with vehicle (DMSO) or three doses of SAHA (100 mg/kg/hr).
  • FIG. 2 is a scan of a Western blot and Coomassie stained gel indicating levels of acetylated histone ( ⁇ AcH4) at the indicated timepoints following treatment with vehicle (DMSO) or three doses of Pyroxamide (100 mg/kg/hr).
  • the present application is directed to a method of treating diseases of the central nervous system (CNS) comprising administering to a individual in need of treatment a therapeutically effective amount of an inhibitor of histone deacetylase.
  • the CNS disease is a neurodegenerative disease.
  • the neurogenerative disease is an inherited neurodegenerative disease, such as those inherited neurodegenerative diseases which are polyglutamine expansion diseases.
  • the neurodegenerative disease is Huntington's disease.
  • the individual can be a mammal such as a primate or human.
  • Therapeutically effective amount refers to an amount which elicits the desired therapeutic effect.
  • the therapeutic effect is dependent upon the disease being treated. As such, the therapeutic effect can be a decrease in the severity of symptoms associated with the disease and/or inhibition (partial or complete) of progression of the disease.
  • the amount needed to elicit the therapeutic response can be determined based on the age, health, size and sex of the patient. Optimal amounts can also be determined based on monitoring of the patient's response to treatment.
  • neurodegenerative diseases of the central nervous system
  • diseases of the central nervous system are referred to as neurodegenerative, indicating that they are characterized by gradually evolving, relentlessly progressive neuronal death occurring for reasons that are still largely unknown.
  • the identification of these diseases depends upon exclusion of such possible causative factors as infections, metabolic derangements, and intoxications.
  • a considerable proportion of the disorders classed as neurogenerative are genetic, with either dominant or recessive inheritance. Others, however, occur only sporadically as isolated instances in a given family.
  • Classification of the degenerative diseases cannot be based upon any exact knowledge of cause or pathogenesis; their subdivision into individual syndromes rests on descriptive criteria based largely upon neuropathologic and clinical aspects. This group of diseases presents as several distinct clinical syndromes, the recognition of which can assist the clinician in arriving at a diagnosis.
  • polyglutamine polyglutamine
  • polyQ polyglutamine
  • the underlying mutation is an expansion of a CAG trinucleotide repeat that encodes polyQ in the respective disease protein. All are progressive, ultimately fatal disorders that typically begin in adulthood and progress over 10 to 30 years.
  • the clinical features and pattern of neuronal degeneration differ among the diseases, yet increasing evidence suggests that polyQ diseases share important pathogenic features.
  • abnormal protein conformations(s) promoted by polyQ expansion seem to be central to pathogenesis.
  • This class of PolyQ expansion neurodegenerative disease are Huntington's Disease (HD), Dentatorubralpallidoluysian atrophy (DRPLA), spinal and bulbar muscular atrophy (SBMA), and five spinocerebellar ataxias (SCA1, SCA2, SCA3/MJD(Machado-Joseph Disease), SCA6 and SCA7). These diseases are listed in the general listing of neurodegenrative disease below. Many of these diseases not yet connected with PolyQ expansion are thought to result from abnormal protein folding and aggregation (e.g., Alzheimer's disease).
  • neurodegenerative diseases can be grouped as follows:
  • Torsion dystonia torsion spasm; dystonia musculorum deformans
  • HDAC inhibitors suitable for use in the invention include, but are not limited to the following specific structures:
  • HDAC inhibitors which can be useful can include the four general classes described above: 1) short-chain fatty acids (e.g., 4-phenylbutyrate and valproic acid); hydroxamic acids (e.g., SAHA, Pyroxamide, trichostatin A (TSA), oxamflatin and CHAPs, such as, CHAP1 and CHAP 31); 3) cyclic tetrapeptides (Trapoxin A and Apicidin; 4) benzamides (e.g., MS-275); and other compounds such as Scriptaid. Examples of such compounds can be found in U.S. Pat. No. 5,369,108, issued on Nov. 29, 1994, U.S. Pat. No.
  • mice (2 mice per condition) were injected by intraperitoneal injection (IP) with either SAHA (100 mg/kg), pyroxamide (200 mg/kg), or vehicle (dimethylsulfoxide). Each mouse was administered three injections at the indicated dose at 1 hour intervals. After the final IP injection tissues (brain, spleen or liver) were isolated at the times indicated. Histones were isolated from tissues essentially as described by Yoshida et al., (1990) J. Biol. Chem. 265:17174-17179. Equal amounts of histones (1 ⁇ g) were electrophoresed on 15% SDS-polyacrylamide gels and transferred to Hybond-P filters (Amersham).
  • IP intraperitoneal injection

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
US10/273,401 2001-10-16 2002-10-16 Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors Abandoned US20040087657A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/273,401 US20040087657A1 (en) 2001-10-16 2002-10-16 Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors
US11/282,420 US7879865B2 (en) 2001-10-16 2005-11-18 Treatment of cancer of the brain using histone deacetylase inhibitors
US13/017,447 US20110124731A1 (en) 2001-10-16 2011-01-31 Treatment Of Neurodegenerative Diseases And Cancer Of The Brain Using Histone Deacetylase Inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32970501P 2001-10-16 2001-10-16
US10/273,401 US20040087657A1 (en) 2001-10-16 2002-10-16 Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/282,420 Division US7879865B2 (en) 2001-10-16 2005-11-18 Treatment of cancer of the brain using histone deacetylase inhibitors

Publications (1)

Publication Number Publication Date
US20040087657A1 true US20040087657A1 (en) 2004-05-06

Family

ID=23286625

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/273,401 Abandoned US20040087657A1 (en) 2001-10-16 2002-10-16 Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors
US11/282,420 Expired - Fee Related US7879865B2 (en) 2001-10-16 2005-11-18 Treatment of cancer of the brain using histone deacetylase inhibitors
US13/017,447 Abandoned US20110124731A1 (en) 2001-10-16 2011-01-31 Treatment Of Neurodegenerative Diseases And Cancer Of The Brain Using Histone Deacetylase Inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/282,420 Expired - Fee Related US7879865B2 (en) 2001-10-16 2005-11-18 Treatment of cancer of the brain using histone deacetylase inhibitors
US13/017,447 Abandoned US20110124731A1 (en) 2001-10-16 2011-01-31 Treatment Of Neurodegenerative Diseases And Cancer Of The Brain Using Histone Deacetylase Inhibitors

Country Status (7)

Country Link
US (3) US20040087657A1 (enExample)
EP (2) EP1443928B1 (enExample)
JP (1) JP4638148B2 (enExample)
AT (1) ATE517624T1 (enExample)
AU (2) AU2002340253C1 (enExample)
CA (1) CA2463552C (enExample)
WO (1) WO2003032921A2 (enExample)

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002506A1 (en) * 1999-09-08 2004-01-01 Sloan Kettering Institute For Cancer Research Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US20040077591A1 (en) * 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
US20040266818A1 (en) * 2003-04-01 2004-12-30 Ronald Breslow Hydroxamic acid compounds and methods of use thereof
US20050075282A1 (en) * 2003-10-01 2005-04-07 Douglas Coulter Materials and methods for inhibiting the development of epilepsy
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US20050137232A1 (en) * 2003-03-17 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US20060079551A1 (en) * 2001-10-16 2006-04-13 Richon Victoria M Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors
US20060205941A1 (en) * 2004-12-16 2006-09-14 Bressi Jerome C Histone deacetylase inhibitors
US20060258694A1 (en) * 2005-05-11 2006-11-16 Bressi Jerome C Histone deacetylase inhibitors
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20070015809A1 (en) * 2005-07-14 2007-01-18 Bressi Jerome C Histone deacetylase inhibitors
US20070173527A1 (en) * 2006-01-13 2007-07-26 Bressi Jerome C Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20070213392A1 (en) * 2003-10-09 2007-09-13 Miller Thomas A Thiophene and Benzothiophene Hydroxamic Acid Derivatives
US20080139535A1 (en) * 2004-04-01 2008-06-12 Miikana Therapeutics Inhibitors of histone deacetylase
US20080214569A1 (en) * 2006-05-02 2008-09-04 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
US20080249179A1 (en) * 2002-03-04 2008-10-09 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20090023718A1 (en) * 2003-11-26 2009-01-22 Aton Pharma, Inc. Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives
US20090023786A1 (en) * 2004-04-05 2009-01-22 Alton Pharma, Inc. Histone Deacetylase Inhibitor Prodrugs
US20090035292A1 (en) * 2007-08-03 2009-02-05 Kovach John S Use of phosphatases to treat neuroblastomas and medulloblastomas
US20090036309A1 (en) * 2007-02-06 2009-02-05 Kovach John S Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use
US20090054720A1 (en) * 2002-04-15 2009-02-26 George Sgouros Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer
US20090143445A1 (en) * 2007-10-01 2009-06-04 John P. White, Esq HDAC Inhibitors
US20090325862A1 (en) * 2006-05-04 2009-12-31 Christian Steinkuhler Histone Deacetylase Inhibitors for the Treatment of Neurodegeneration
US20100029683A1 (en) * 2008-08-01 2010-02-04 Kovach John S Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses
US20100029484A1 (en) * 2008-08-01 2010-02-04 Kovach John S Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US20100029640A1 (en) * 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US20100075926A1 (en) * 2008-07-23 2010-03-25 Li-Huei Tsai Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival
US20100093867A1 (en) * 2006-07-05 2010-04-15 Ryoichi Matsuda Method Of Treating Genetic Disease Caused By Nonsense Mutation
US20100113602A1 (en) * 2007-02-27 2010-05-06 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Use of histone deacetylase inhibitors for the treatment of central nervous system metastases
US7772245B2 (en) 2005-02-14 2010-08-10 Miikana Therapeutics, Inc. Inhibitors of histone deacetylase
US20100278730A1 (en) * 2007-04-12 2010-11-04 Sabrina Ronen Non-Invasive Molecular Imaging of Cellular Histone Deacetylase Substrate Using Magnetic Resonance Spectroscopy (MRS) or Positron Emission Tomography (PET)
US20110009475A1 (en) * 2007-07-13 2011-01-13 Massachusetts Institute Of Technology Methods for treating stress induced emotional disorders
US20110224303A1 (en) * 2009-10-30 2011-09-15 Li-Huei Tsai Use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders
US8088951B2 (en) 2006-11-30 2012-01-03 Massachusetts Institute Of Technology Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
US8263547B2 (en) 2008-05-28 2012-09-11 Massachusetts Institute Of Technology DISC-1 pathway activators in the control of neurogenesis
WO2013066836A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
US9115053B2 (en) 2011-07-22 2015-08-25 Massachusetts Institute Of Technology Activators of class I histone deacetlyases (HDACS) and uses thereof
US11453661B2 (en) 2019-09-27 2022-09-27 Takeda Pharmaceutical Company Limited Heterocyclic compound
US11931354B2 (en) 2013-04-09 2024-03-19 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
US12168008B2 (en) 2016-12-08 2024-12-17 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322160A1 (en) * 2002-03-04 2011-05-18 Merck HDAC Research, LLC Methods of inducing terminal differentiation
JP2006512318A (ja) * 2002-11-12 2006-04-13 アルコン，インコーポレイテッド 眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター
GB0226855D0 (en) * 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
US20080004290A1 (en) * 2003-11-28 2008-01-03 The University Of Queensland Anti-Cancer Agents
CN101035542A (zh) * 2004-08-25 2007-09-12 默克公司 组蛋白脱乙酰基酶抑制剂
US7901675B2 (en) 2004-10-13 2011-03-08 U.S. Department Of Veterans Affairs Method of using coenzyme Q10 to treat Huntington's disease
AU2006228957A1 (en) * 2005-04-01 2006-10-05 Methylgene Inc. Inhibitors of histone deacetylase
WO2006117165A2 (en) * 2005-05-02 2006-11-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Means and methods for the treatment of head injuries and stroke
TWI415603B (zh) * 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
US8158825B2 (en) 2005-06-24 2012-04-17 Merck Sharp & Dohme Corp. Modified malonate derivatives
US20090105329A1 (en) * 2005-11-04 2009-04-23 Judy Chiao Methods of Treating Cancers with SAHA, Carboplatin, and Paclitaxel and Other Combination Therapies
CA2667826C (en) 2006-10-28 2013-10-08 Methylgene Inc. Inhibitors of histone deacetylase
CN102775368B (zh) * 2011-05-10 2016-08-17 上海驺虞医药科技有限公司 一类噻唑类化合物及其制备方法和用途
WO2019140417A1 (en) * 2018-01-15 2019-07-18 Daly Thomas P Aminopyridine based buffers with wide buffering ranges antibiotics and myelin disease therapy
WO2023287984A1 (en) * 2021-07-14 2023-01-19 University Of Maryland, Baltimore Suberoylanilide hydroxamic acid (saha) drugs, conjugates, and nanoparticles, and methods of use thereof
KR102859315B1 (ko) * 2024-02-27 2025-09-12 주식회사 아이피에스바이오 히스톤 탈아세틸효소 저해제를 포함하는 다중 글루타민 질병의 예방 또는 치료용 약학적 조성물
KR20250131624A (ko) * 2024-02-27 2025-09-03 주식회사 아이피에스바이오 히스톤 탈아세틸효소 저해제를 포함하는 인지기능 장애의 예방 또는 치료용 약학적 조성물

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330744A (en) * 1988-11-14 1994-07-19 Sloan-Kettering Institute For Cancer Research Method for increasing sensitivity to chemically induced terminal differentiation
US5608108A (en) * 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5668179A (en) * 1988-11-14 1997-09-16 The Trustees Of Columbia University In The City Of New York Potent inducers of terminal differentiation and method of use thereof
US5932616A (en) * 1991-10-04 1999-08-03 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US20020061860A1 (en) * 2000-03-24 2002-05-23 Zuomei Li Antisense oligonucleotide inhibition of specific histone deacetylase isoforms
US20020065282A1 (en) * 2000-07-12 2002-05-30 Guy Georges Tetralone derivatives
US20020103192A1 (en) * 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
US20020142859A1 (en) * 1999-11-01 2002-10-03 Callaway Golf Company Multiple material golf club head
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6511990B1 (en) * 1999-09-08 2003-01-28 Sloan-Kettering Institute For Cancer Research Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US6656905B1 (en) * 1998-10-13 2003-12-02 Fujisawa Pharmaceutical Co., Ltd. Cyclic tetrapeptide compound and use thereof
US20040077591A1 (en) * 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
WO1990009092A2 (en) 1988-11-14 1990-08-23 The Trustees Of Columbia University In The City Of New York Novel potent inducers of terminal differentiation and method of use thereof
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
USRE38506E1 (en) * 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
JPH07196686A (ja) 1994-01-06 1995-08-01 Takeda Chem Ind Ltd 化合物ｔａｎ−１７４６類、その製造法および用途
EP0855024A4 (en) 1995-09-20 2001-08-22 Merck & Co Inc HISTONE DEACETYLASE AS THE ATTACK POINT FOR ANTIPROTOZOIC ACTIVE SUBSTANCES
GB2309696B (en) 1996-01-31 2000-02-23 Merck & Co Inc Antiprotozoal cyclic tetrapeptides
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
EP0931792B1 (en) 1998-01-27 2004-01-07 Nisshin Seifun Group Inc. Depsipeptides containing non-natural amino acids
JP4405602B2 (ja) * 1998-04-16 2010-01-27 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ヒストン脱アセチル化酵素阻害剤
JPH11335375A (ja) * 1998-05-20 1999-12-07 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
AUPP505798A0 (en) * 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance
ATE275956T1 (de) 1998-10-19 2004-10-15 Methylgene Inc Veränderung der dns methyltransferase durch kombinationstherapie
JP2000256194A (ja) * 1999-01-06 2000-09-19 Mitsui Chemicals Inc 核内レセプタ作動薬およびその効果増強剤
JP4269041B2 (ja) 1999-03-02 2009-05-27 国立大学法人九州工業大学 新規な環状テトラペプチド誘導体とその医薬用途
JP2003500052A (ja) 1999-05-03 2003-01-07 メチルジーン インコーポレイテッド ヒストン脱アセチル酵素の抑制
WO2001014581A2 (en) 1999-08-20 2001-03-01 Board Of Regents, The University Of Texas System Hdac4 and hdac5 in the regulation of cardiac gene expression
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
DE60034688T2 (de) 1999-09-08 2008-01-17 Sloan-Kettering Institute For Cancer Research Kristallstruktur einer deacetylase und deren inhibitoren
US6541661B1 (en) 1999-11-23 2003-04-01 Methylgene, Inc. Inhibitors of histone deacetylase
WO2001042437A2 (en) 1999-12-08 2001-06-14 Axys Pharmaceuticals, Inc. Histone deacetylase-8 proteins, nucleic acids, and methods of use
ATE489360T1 (de) 2000-03-24 2010-12-15 Methylgene Inc Inhibitoren der histon-deacetylase
JP2001348340A (ja) 2000-06-07 2001-12-18 Yamanouchi Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害剤
JP2001354694A (ja) * 2000-06-13 2001-12-25 Yamanouchi Pharmaceut Co Ltd ジチオール誘導体
ES2277923T3 (es) * 2000-07-06 2007-08-01 Sumitomo Chemical Company, Limited Insecticidas.
EP1170008A1 (en) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors
AU2001285042A1 (en) 2000-08-18 2002-03-04 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US20050004007A1 (en) * 2000-09-12 2005-01-06 Steven Grant Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents
WO2002030879A2 (en) 2000-09-29 2002-04-18 Prolifix Limited Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
EP2083005A1 (en) 2000-09-29 2009-07-29 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
WO2002055017A2 (en) * 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
WO2002050285A2 (en) 2000-12-20 2002-06-27 Novartis Ag Histone deacetylase-related gene and protein
AR035513A1 (es) 2000-12-23 2004-06-02 Hoffmann La Roche Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
WO2002090534A1 (en) 2001-05-02 2002-11-14 The Regents Of The University Of California Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors
US20040142859A1 (en) * 2002-05-02 2004-07-22 Steffan Joan S. Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors
AU2002318364A1 (en) * 2001-06-14 2003-01-02 Bristol-Myers Squibb Company Novel human histone deacetylases
JP4638148B2 (ja) * 2001-10-16 2011-02-23 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 神経変性疾患および脳の癌の処置
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
EP1482962A4 (en) * 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX)
EP2322160A1 (en) * 2002-03-04 2011-05-18 Merck HDAC Research, LLC Methods of inducing terminal differentiation
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
MXPA04010199A (es) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Terapia en combinacion para el tratamiento de cancer.
JP2006508986A (ja) * 2002-11-20 2006-03-16 エルラント ゲネ セラペウチクス エルエルシー ヒストンデアセチラーゼ阻害剤による肺細胞の治療方法
WO2004089293A2 (en) * 2003-04-01 2004-10-21 Memorial Sloan-Kettering Cancer Center Hydroxamic acid compounds and methods of use thereof
CN1964714B (zh) * 2003-08-29 2011-09-28 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途
WO2007136615A2 (en) * 2006-05-16 2007-11-29 Merck & Co., Inc. Combination cancer therapy

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330744A (en) * 1988-11-14 1994-07-19 Sloan-Kettering Institute For Cancer Research Method for increasing sensitivity to chemically induced terminal differentiation
US5608108A (en) * 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5668179A (en) * 1988-11-14 1997-09-16 The Trustees Of Columbia University In The City Of New York Potent inducers of terminal differentiation and method of use thereof
US5840960A (en) * 1988-11-14 1998-11-24 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5932616A (en) * 1991-10-04 1999-08-03 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US6087367A (en) * 1991-10-04 2000-07-11 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US6656905B1 (en) * 1998-10-13 2003-12-02 Fujisawa Pharmaceutical Co., Ltd. Cyclic tetrapeptide compound and use thereof
US6511990B1 (en) * 1999-09-08 2003-01-28 Sloan-Kettering Institute For Cancer Research Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US20020142859A1 (en) * 1999-11-01 2002-10-03 Callaway Golf Company Multiple material golf club head
US20020061860A1 (en) * 2000-03-24 2002-05-23 Zuomei Li Antisense oligonucleotide inhibition of specific histone deacetylase isoforms
US20020065282A1 (en) * 2000-07-12 2002-05-30 Guy Georges Tetralone derivatives
US20020103192A1 (en) * 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US20040077591A1 (en) * 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241129A1 (en) * 1999-09-08 2006-10-26 Ronald Breslow Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US7126001B2 (en) * 1999-09-08 2006-10-24 Sloan-Kettering Institute For Cancer Research Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US20070010536A1 (en) * 1999-09-08 2007-01-11 Ronald Breslow Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US7345174B2 (en) 1999-09-08 2008-03-18 Sloan-Kettering Institute For Cancer Research Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US20040002506A1 (en) * 1999-09-08 2004-01-01 Sloan Kettering Institute For Cancer Research Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
US7879865B2 (en) 2001-10-16 2011-02-01 Sloan-Kettering Institute For Cancer Research Treatment of cancer of the brain using histone deacetylase inhibitors
US20060079551A1 (en) * 2001-10-16 2006-04-13 Richon Victoria M Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors
US20110124731A1 (en) * 2001-10-16 2011-05-26 Sloan-Kettering Institute For Cancer Research Treatment Of Neurodegenerative Diseases And Cancer Of The Brain Using Histone Deacetylase Inhibitors
US20080249179A1 (en) * 2002-03-04 2008-10-09 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US20040077591A1 (en) * 2002-03-28 2004-04-22 The Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
US20090054720A1 (en) * 2002-04-15 2009-02-26 George Sgouros Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer
US7399884B2 (en) 2002-10-08 2008-07-15 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050137232A1 (en) * 2003-03-17 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7199134B2 (en) 2003-04-01 2007-04-03 Sloan-Kettering Institute For Cancer Research Hydroxamic acid compounds and methods of use thereof
US20070155785A1 (en) * 2003-04-01 2007-07-05 Ronald Breslow Hydroxamic acid compounds and methods of use thereof
US20040266818A1 (en) * 2003-04-01 2004-12-30 Ronald Breslow Hydroxamic acid compounds and methods of use thereof
US7799803B2 (en) 2003-04-01 2010-09-21 The Trustees Of Columbia University In The City Of New York Hydroxamic acid compounds and methods of use thereof
US20050075282A1 (en) * 2003-10-01 2005-04-07 Douglas Coulter Materials and methods for inhibiting the development of epilepsy
US7935724B2 (en) 2003-10-09 2011-05-03 Merck Hdac Research, Llc Thiophene and benzothiophene hydroxamic acid derivatives
US20070213392A1 (en) * 2003-10-09 2007-09-13 Miller Thomas A Thiophene and Benzothiophene Hydroxamic Acid Derivatives
US20090023718A1 (en) * 2003-11-26 2009-01-22 Aton Pharma, Inc. Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US20050250784A1 (en) * 2004-03-08 2005-11-10 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US20080139535A1 (en) * 2004-04-01 2008-06-12 Miikana Therapeutics Inhibitors of histone deacetylase
US8227636B2 (en) 2004-04-05 2012-07-24 Merck Hdac Research, Llc Histone deacetylase inhibitor prodrugs
US20090023786A1 (en) * 2004-04-05 2009-01-22 Alton Pharma, Inc. Histone Deacetylase Inhibitor Prodrugs
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20060205941A1 (en) * 2004-12-16 2006-09-14 Bressi Jerome C Histone deacetylase inhibitors
US7772245B2 (en) 2005-02-14 2010-08-10 Miikana Therapeutics, Inc. Inhibitors of histone deacetylase
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20060258694A1 (en) * 2005-05-11 2006-11-16 Bressi Jerome C Histone deacetylase inhibitors
US20080119648A1 (en) * 2005-07-14 2008-05-22 Bressi Jerome C Histone deacetylase inhibitors
US20080108829A1 (en) * 2005-07-14 2008-05-08 Bressi Jerome C Histone deacetylase inhibitors
US20080114037A1 (en) * 2005-07-14 2008-05-15 Bressi Jerome C Histone deacetylase inhibitors
US20090111996A1 (en) * 2005-07-14 2009-04-30 Bressi Jerome C Histone deacetylase inhibitors
US20070015809A1 (en) * 2005-07-14 2007-01-18 Bressi Jerome C Histone deacetylase inhibitors
US7741494B2 (en) 2005-07-14 2010-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20080119658A1 (en) * 2005-07-14 2008-05-22 Bressi Jerome C Histone deacetylase inhibitors
US20070173527A1 (en) * 2006-01-13 2007-07-26 Bressi Jerome C Histone deacetylase inhibitors
US20080214569A1 (en) * 2006-05-02 2008-09-04 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
US20090325862A1 (en) * 2006-05-04 2009-12-31 Christian Steinkuhler Histone Deacetylase Inhibitors for the Treatment of Neurodegeneration
US20100093867A1 (en) * 2006-07-05 2010-04-15 Ryoichi Matsuda Method Of Treating Genetic Disease Caused By Nonsense Mutation
US8088951B2 (en) 2006-11-30 2012-01-03 Massachusetts Institute Of Technology Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
US9079917B2 (en) 2007-02-06 2015-07-14 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US8426444B2 (en) 2007-02-06 2013-04-23 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US8822461B2 (en) 2007-02-06 2014-09-02 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US10023587B2 (en) 2007-02-06 2018-07-17 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US7998957B2 (en) 2007-02-06 2011-08-16 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use
US20090036309A1 (en) * 2007-02-06 2009-02-05 Kovach John S Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use
US10399993B2 (en) 2007-02-06 2019-09-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US20100113602A1 (en) * 2007-02-27 2010-05-06 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Use of histone deacetylase inhibitors for the treatment of central nervous system metastases
US20100278730A1 (en) * 2007-04-12 2010-11-04 Sabrina Ronen Non-Invasive Molecular Imaging of Cellular Histone Deacetylase Substrate Using Magnetic Resonance Spectroscopy (MRS) or Positron Emission Tomography (PET)
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
EP3103791A1 (en) 2007-06-27 2016-12-14 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20110009475A1 (en) * 2007-07-13 2011-01-13 Massachusetts Institute Of Technology Methods for treating stress induced emotional disorders
US20090035292A1 (en) * 2007-08-03 2009-02-05 Kovach John S Use of phosphatases to treat neuroblastomas and medulloblastomas
US8455688B2 (en) 2007-10-01 2013-06-04 Lixte Biotechnology, Inc. HDAC inhibitors
US8143445B2 (en) 2007-10-01 2012-03-27 Lixte Biotechnology, Inc. HDAC inhibitors
US20090143445A1 (en) * 2007-10-01 2009-06-04 John P. White, Esq HDAC Inhibitors
US10124035B2 (en) 2008-05-28 2018-11-13 Massachusetts Institute Of Technology DISC-1 pathway activators in the control of neurogenesis
US8263547B2 (en) 2008-05-28 2012-09-11 Massachusetts Institute Of Technology DISC-1 pathway activators in the control of neurogenesis
US20100075926A1 (en) * 2008-07-23 2010-03-25 Li-Huei Tsai Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US8329719B2 (en) 2008-08-01 2012-12-11 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US8541458B2 (en) 2008-08-01 2013-09-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US8058268B2 (en) 2008-08-01 2011-11-15 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US20100029683A1 (en) * 2008-08-01 2010-02-04 Kovach John S Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses
US20100029640A1 (en) * 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US20100029484A1 (en) * 2008-08-01 2010-02-04 Kovach John S Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US8841346B2 (en) 2009-10-30 2014-09-23 Massachusetts Institute Of Technology Use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders
US8563615B2 (en) 2009-10-30 2013-10-22 Massachusetts Institute Of Technology Use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders
US20110224303A1 (en) * 2009-10-30 2011-09-15 Li-Huei Tsai Use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders
US9115053B2 (en) 2011-07-22 2015-08-25 Massachusetts Institute Of Technology Activators of class I histone deacetlyases (HDACS) and uses thereof
US10167277B2 (en) 2011-07-22 2019-01-01 Massachusetts Institute Of Technology Activators of class I histone deacetlyases (HDACs) and uses thereof
US11084803B2 (en) 2011-07-22 2021-08-10 Massachusetts Institute Of Technology Activators of class I histone deacetylases (HDACs) and uses thereof
WO2013066836A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
US11931354B2 (en) 2013-04-09 2024-03-19 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
US12343342B2 (en) 2013-04-09 2025-07-01 Lixte Biotechnology, Inc. Methods for treating soft tissue sarcoma
US12168008B2 (en) 2016-12-08 2024-12-17 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
US11453661B2 (en) 2019-09-27 2022-09-27 Takeda Pharmaceutical Company Limited Heterocyclic compound
US11958845B2 (en) 2019-09-27 2024-04-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
US12384770B2 (en) 2019-09-27 2025-08-12 Takeda Pharmaceutical Company Limited Heterocyclic compound

Also Published As

Publication number Publication date
EP1443928B1 (en) 2011-07-27
EP2269609A2 (en) 2011-01-05
AU2006200326B2 (en) 2008-08-21
US20110124731A1 (en) 2011-05-26
AU2002340253C1 (en) 2011-03-31
CA2463552C (en) 2011-05-17
WO2003032921A2 (en) 2003-04-24
JP2005506348A (ja) 2005-03-03
EP1443928A2 (en) 2004-08-11
AU2002340253B2 (en) 2005-10-27
CA2463552A1 (en) 2003-04-24
ATE517624T1 (de) 2011-08-15
US20060079551A1 (en) 2006-04-13
WO2003032921A3 (en) 2003-10-30
JP4638148B2 (ja) 2011-02-23
AU2006200326A1 (en) 2006-02-16
EP1443928A4 (en) 2007-04-18
US7879865B2 (en) 2011-02-01
EP2269609A3 (en) 2012-07-11

Similar Documents

Publication Publication Date Title
US7879865B2 (en) Treatment of cancer of the brain using histone deacetylase inhibitors
AU2002340253A1 (en) Treatment of neurodegenerative diseases and cancer of the brain
ES2984267T3 (es) Formulaciones de oxabicicloheptanos y oxabicicloheptenos
US20200179313A1 (en) Composition and method for the treatment of neurological diseases and cerebral injury
JP2024015132A (ja) Ｏ－環状フィトスフィンゴシン－１－フォスフェートを含むパーキンソン病の予防又は治療用組成物
JP2016537375A (ja) 神経変性疾患または認知障害を治療するためのインドリルおよびインドリニルヒドロキサメートの使用
WO2008042795A2 (en) Histone acetyle transferase activators and histone deacetylase inhibitors in the treatment of alcoholism
US7429560B2 (en) Ketoamide inhibitors in chronic nerve disease
US20250064948A1 (en) Gcpii inhibition for the treatment of sarcopenia and aging
D'Hooge et al. The uremic quanidino compound guanidinosuccinic acid induces behavioral convulsions and concomitant epileptiform electrocorticographic discharges in mice
BR112019010210A2 (pt) melhora na atividade locomotora e aumento da longevidade de indivíduos com lipofuscinose ceroide neuronal infantil tardia por gemfibrozil
WO2013148740A1 (en) 4–aminopyridine as a therapeutic agent for spinal muscular atrophy
US20080207697A1 (en) Use of Epothilones in the Treatment of Neuronal Connectivity Defects Such as Schizophrenia and Autism
US11351229B2 (en) Combination therapies for treating infantile spasms and other treatment resistant epilepsies
KR102633592B1 (ko) 자폐 스펙트럼 장애의 예방 또는 치료용 약학적 조성물 및 이를 이용한 자폐 스펙트럼 장애 치료방법
US20200261384A1 (en) Memory manipulation via modification of protein kinase c zeta activity
CN114984034A (zh) 一种寡糖类化合物的应用
Andersson Physiology and Pharmacology of the Bladder
HK1152658A (en) Treatment of neurodegenerative diseases and cancer of the brain with saha
EP2453890B1 (en) Compositions comprising a cholinesterase inhibitor for treating cognitive disorders
WO2020186505A1 (zh) 丹参酮IIA在抑制Tau蛋白异常聚集中的应用
TW201929850A (zh) 醫藥組成物於製備預防或治療不正常乙型-澱粉樣蛋白聚集類疾病之藥物上之用途
HK40012894A (en) Improvement in locomotor activity and increase in longevity of late infantile neuronal ceriod lipofuscinosis subjects by gemfibrozil

Legal Events

Date Code Title Description
AS Assignment

Owner name: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, NEW

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RICHON, VICTORIA M.;MARKS, PAUL A.;RIFKIND, RICHARD A.;REEL/FRAME:014461/0971;SIGNING DATES FROM 20030212 TO 20030827

AS Assignment

Owner name: SLOAN-KETTING INSTITUTE FOR CANCER RESEARCH, NEW Y

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RICHON, VICTORIA A.;MARKS, PAUL A.;RIFKIND, RICHARD A;REEL/FRAME:014883/0454;SIGNING DATES FROM 20030212 TO 20030827

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION